Budd-Chiari syndrome

Méndez-Sánchez, Nahúm; Chávez-Tapia, Norberto C.; López-Méndez, Eric; Uribe, Misael

doi:10.1016/s1665-2681(19)32067-8

Cited by 2 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other risk factors associated with NAFLD are waist circumference, hyperinsulinemia, hypertriglyceridemia, and impaired glucose tolerance or T2DM [38,39]. The clinical implications of NAFLD derive mostly from its common occurrence in the general population and its potential to progress to fibrosis, cirrhosis, and liver failure [14].…”

Section: Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

“…Recently, other insulin-resistance-associated diseases have been included on this list [4-6, 14, 42, 69, 70], such as NAFLD [5,14,42] and gallstone disease [4,6,69,70], which share all the pathogenic mechanisms involved in previous pathological states, of which insulin resistance is the hallmark [5,14]. Recently, we reported that high levels of adiponectin are associated with a protective effect against hepatic steatosis [42].…”

Section: Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

“…Important changes have been described in the epidemiology of obesity and related disorders [1][2][3][4][5][6]. Between 1990 and 2000, the age-adjusted prevalence of obesity increased from 22.9% to 30.5% and the age-adjusted prevalence of overweight increased from 55.9% to 64.5% [7].…”

Section: Introductionmentioning

confidence: 99%

“…A number of genetic and biochemical disturbances have facilitated our understanding of one of the most important associated abnormalities, namely, insulin resistance [13]. Hepatobiliary expression of insulin resistance includes mainly gallstone disease [6] and nonalcoholic fatty liver disease [14]. However, obesity and insulin resistance have deleterious effects on all chronic liver diseases [15], and participate in the production of biliary sludge during pregnancy [15].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hepatobiliary Diseases and Insulin Resistance

Méndez-Sánchez

Chavez-Tapia²,

Zamora-Valdés³

et al. 2007

CMC

View full text Add to dashboard Cite

In recent years, there has been an increasing prevalence of obesity and related diseases. This epidemiological change has increased the interest of researchers in the molecular and biochemical pathways involved in the pathogenesis of hepatic and biliary diseases. Insulin resistance is considered the major mechanism involved in the hepatic and biliary manifestations of obesity. Epidemiological, clinical, and basic research demonstrates that insulin resistance is associated with gallstone disease, nonalcoholic fatty liver disease, and poor outcomes in viral hepatitis C treatments. Fascinating experimental evidence demonstrates that fat-induced hepatic insulin resistance may result from the activation of kinases leading to impaired insulin signaling. The insulin-resistant state is characterized by a failure to suppress hepatic glucose production and glycogenolysis, with enhanced fat accumulation in hepatocytes because of increased lipolysis, increased free fatty acid uptake by hepatocytes, and increased hepatic synthesis of triglycerides. This molecular signaling induces a low-grade chronic inflammatory state, characterized by increased levels of proinflammatory molecules and acute-phase proteins. This review summarizes the most important molecular and biochemical issues in the hepatic and biliary diseases associated with insulin resistance.

show abstract

Section: Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

Section: Nonalcoholic Fatty Liver Diseasementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hepatobiliary Diseases and Insulin Resistance

Méndez-Sánchez

Chavez-Tapia²,

Zamora-Valdés³

et al. 2007

CMC

View full text Add to dashboard Cite

show abstract

“…Experimental studies suggest that adiponectin plays a major role in the pathophysiology of insulin resistance and the metabolic syndrome [15,16]. Insulin resistance causes abnormalities on lipid storage and lipolysis in insulin-sensitive tissues, which may induce an increased flux of free fatty acids from adipose tissue to the liver and cause steatosis [17,18].…”

Section: Introductionmentioning

confidence: 99%

Adiponectin, Structure, Function and Pathophysiological Implications in Non-Alcoholic Fatty Liver Disease

Méndez-Sánchez¹,

Chavez-Tapia²,

Zamora-Valdés³

et al. 2006

MRMC

View full text Add to dashboard Cite

Obesity is a major risk factor for the development of the metabolic syndrome, a cluster of diseases including insulin resistance, type 2 diabetes, dyslipidemia, hypertension, microalbuminuria, atherosclerosis, and non-alcoholic steatohepatitis. On the other hand, it is now generally accepted that adipose tissue acts as an endocrine organ producing a number of substances with an important role in the regulation of food intake, energy expenditure and a series of metabolic processes. Adiponectin is a recently discovered hormone produced exclusively by adipocytes. In fact, adiponectin is considered currently as a major factor in obesity-related insulin resistance and atherosclerosis. This new hormone differs from other adipocytokines in that its production and concentrations are actually decreased in insulin resistant subjects. The aim of this review is to summarize the current knowledge about the chemistry and physiology of adiponectin and to discuss its implications in the pathophysiology and potential treatment of insulin resistance and non-alcoholic fatty liver disease.

show abstract

Budd-Chiari syndrome

Cited by 2 publications

References 4 publications

Hepatobiliary Diseases and Insulin Resistance

Hepatobiliary Diseases and Insulin Resistance

Adiponectin, Structure, Function and Pathophysiological Implications in Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About